Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Use of Single-use Preservative-free Tafluprost Eye Drops
TCTR20210224008Phase 3Not yet recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tafluprost in Glaucoma, ocular hypertension, sponsored by Ratchadaphiseksomphot Endowment Fund. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
tafluprost
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on TCTR20210224008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210224008.